Join to view full profile
60 First StreetCambridge, MA 02141
Dr. Olugemo is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Olukemi (Ajayi) Olugemo is a neurologist based in Cambridge, MA, with subspecialties in neuroimmunology/multiple sclerosis, neuromuscular medicine, neurodegenerative, and neurodevelopmental disabilities. She completed her medical education and training at the University of Maryland, where she interned in internal medicine and completed her residency in neurology. Her clinical expertise includes stroke, multiple sclerosis, neuromuscular disease, and epileptology. Dr. Olugemo has published numerous articles in reputable journals, including those focused on CNS trials during the COVID-19 pandemic and the long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis. Her involvement in clinical trials includes studies on various neurological conditions, such as Angelman Syndrome and hereditary transthyretin-mediated amyloid polyneuropathy.
Education & Training
University of MarylandResidency, Neurology, 2004 - 2007- University of MarylandInternship, Internal Medicine, 2003 - 2004
University of Maryland School of MedicineClass of 2003
Certifications & Licensure
VA State Medical License 2019 - 2028
MD State Medical License 2006 - 2018
AOA Board of Neurology and Psychiatry Neurology
American Academy of NeurologyFellow
Clinical Trials
- Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
- A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease
- Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Publications & Presentations
PubMed
- 2 citationsConducting CNS trials during a public health emergency - Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper.Kemi Olugemo, Dragana Bugarski-Kirola, Gerard R Dawson, Franco DiCesare, Dejan Stevanović
Neuroscience Applied. 2023-01-01 - 29 citationsLong-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.Thomas H Brannagan, Teresa Coelho, Annabel K Wang, Michael J Polydefkis, Peter J Dyck
Journal of Neurology. 2022-12-01 - 13 citationsATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.Thomas H. Brannagan, Michaela Auer-Grumbach, John L. Berk, Chiara Briani, Vera Bril
Orphanet Journal of Rare Diseases. 2021-05-06
Books/Book Chapters
Press Mentions
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testingNovember 13th, 2025
Timmerman Traverse for Life Sciences Cares Raises another $1.1M to fight Poverty in 2025August 24th, 2025
Korro Bio Receives European Medicines Agency Orphan Drug Designation for KRRO-110 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)July 22nd, 2025
Committees
- Scientific Committee Member, International Society of CNS Clinical Trials and Methology (ISCTM) 2019 - Present
- Leadership Council, CNS Summit 2019 - Present
Industry Relationships
- Head of Clinical Development, Laronde
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: